State Street
OKUR

State Street’s OnKure Therapeutics OKUR Stock Holding History

State Street’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Buy
463,662
+450,200
+3,344% +$1.93M ﹤0.01% 3319
2026
Q1 		$55.7K Buy
+13,462
New +$41.6K ﹤0.01% 4114
2024
Q4 		– Sell
-7,164
Closed -$122K – 4325
2024
Q3 		$122K Hold
7,164
– – ﹤0.01% 3938
2024
Q2 		$108K Sell
7,164
-17,579
-71% -$298K ﹤0.01% 3994
2024
Q1 		$411K Hold
24,743
– – ﹤0.01% 3700
2023
Q4 		$396K Buy
24,743
+2,939
+13% +$183K ﹤0.01% 3695
2023
Q3 		$1.66M Buy
21,804
+642
+3% +$43.7K ﹤0.01% 3401
2023
Q2 		$1.39M Buy
21,162
+19,522
+1,190% +$1.57M ﹤0.01% 3524
2023
Q1 		$98.1K Hold
1,640
– – ﹤0.01% 4332
2022
Q4 		$38.2K Hold
1,640
– – ﹤0.01% 4619
2022
Q3 		$55K Hold
1,640
– – ﹤0.01% 4636
2022
Q2 		$43K Sell
1,640
-7,285
-82% -$170K ﹤0.01% 4751
2022
Q1 		$262K Buy
8,925
+119
+1% +$6.66K ﹤0.01% 4290
2021
Q4 		$753K Buy
8,806
+205
+2% +$15.1K ﹤0.01% 3881
2021
Q3 		$641K Buy
8,601
+2,509
+41% +$213K ﹤0.01% 3894
2021
Q2 		$568K Buy
+6,092
New +$679K ﹤0.01% 3810

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's OKUR Position: Q2 2026 in Review

State Street increased its OnKure Therapeutics (OKUR) stake by 3,344% in Q2 2026, buying an estimated $1.93M and bringing the position to 463,662 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3319.

State Street first reported a position in OKUR in Q2 2021 and has held it in 16 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • State Street held 463,662 shares of OnKure Therapeutics worth $2.11M as of Q2 2026.
  • State Street bought 450,200 OnKure Therapeutics shares in Q2 2026, an estimated $1.93M.
  • OnKure Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3319 holding.
  • State Street first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.